1 / 15

Chapter 31

Chapter 31. Chapter 31. Male Genitourinary Agents. Drug Overview. Benign Prostatic Hyperplasia α 1 -Adrenergic antagonist α 1A -Selective: tamsulosin (Flomax) Long-acting α 1 : doxazosin (Cardura) Short-acting α 1 : prazosin (Minipress) 5α-Reductase inhibitors finasteride (Proscar)

Jimmy
Download Presentation

Chapter 31

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 31 Chapter 31 Male Genitourinary Agents

  2. Drug Overview • Benign Prostatic Hyperplasia • α1-Adrenergic antagonist • α1A-Selective: tamsulosin (Flomax) • Long-acting α1: doxazosin (Cardura) • Short-acting α1: prazosin (Minipress) • 5α-Reductase inhibitors • finasteride (Proscar) • dutasteride (Avodart)

  3. Drug Overview • Erectile Dysfunction (ED) • PDE5 inhibitor • sildenafil (Viagra) • tadalafil (Cialis) • vardenafil (Levitra) • Other • alprostadil (Caverject) • yohimbine (Yocon)

  4. Drug Overview • Drugs for Benign Prostatic Hyperplasia • Mechanism of action • Nonspecific α1-adrenergic receptor blockers • α1A-Selective • 5α-Reductase inhibitors

  5. Drug Overview • Drugs for Benign Prostatic Hyperplasia (cont’d) • Treatment principles • Standardized guidelines • The Agency for Healthcare Research and Quality (AHRQ) Guideline on Benign Prostate Hyperplasia: Diagnosis and Treatment • The American Urological Association • Evidence-based recommendations • Cardinal points of treatment

  6. Drug Overview • Drugs for Benign Prostatic Hyperplasia • Treatment principles (cont’d) • How to monitor • Patient variables • Geriatrics • Pregnancy and lactation • Patient education

  7. Drugs for BPH • α-Adrenergic Antagonists • tamsulosin (Flomax) • Contraindications • Warnings/precautions • Pharmacokinetics • Drug interactions • Dosage and administration • Other drugs in class

  8. Drugs for BPH • Androgen Hormone Inhibitor • finasteride (Proscar) • Contraindications • Warnings/precautions • Drug interactions • Dosage and administration

  9. Drugs for ED • Indications and Mechanism of Action • PDE5 inhibitors • alprostadil (Caverject) • yohimbine (Yocon) • Treatment Principles • Standardized guidelines • Montague DK et al: Erectile Dysfunction Guideline Update Panel: The management of erectile dysfunction: an update, Linthicum, MD, 2006, American Urologic Association Education and Research, Inc.

  10. Drugs for ED • Treatment Principles (cont’d) • Evidence-based recommendations • Cardinal points of treatment • Nonpharmacologic treatment • Vascular reconstruction • Vacuum constriction devices • Implanted penile prostheses

  11. Drugs for ED • Treatment Principles (cont’d) • Pharmacologic treatment • Hormone replacement • PDE5 inhibitors • Intraurethral prostaglandin • Yohimbine

  12. Drugs for ED • Treatment Principles (cont’d) • How to monitor • Patient variables • Geriatrics • Pregnancy and lactation • Pediatrics

  13. PDE5 Inhibitors • sildenafil (Viagra) • Contraindications • Warnings/precautions • Drug interactions • Patient education • Other drugs in class • vardenafil • tadalafil

  14. Other ED Drugs • alprostadil (Muse) • Contraindications • Warnings • Drug interactions • Overdosage • Patient education • Dosage and administration

  15. Other ED Drugs • yohimbine (Yocon) • Contraindications • Warnings • Adverse effects • Drug interactions • Overdosage • Dosage and administration

More Related